Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Extended Adjuvant Treatment Strategy in Early Breast Cancer

The Extended Adjuvant Treatment Strategy in Early Breast Cancer Adjuvant tamoxifen has a significant survival benefit in early breast cancer but current data suggest that there is no further benefit beyond 5 years’ treatment. Extended adjuvant therapy with oral letrozole 2.5mg daily following 5 years of tamoxifen in postmenopausal women with hormone receptor-positive breast cancer was shown to significantly reduce the risk of recurrence compared with placebo in the MA-17 trial (predicted 4-year disease-free survival 95% vs 90%). A small but significant overall survival benefit has also emerged in the subset of patients with node-positive disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

The Extended Adjuvant Treatment Strategy in Early Breast Cancer

American Journal of Cancer , Volume 5 (1) – Aug 10, 2012

Loading next page...
 
/lp/springer-journals/the-extended-adjuvant-treatment-strategy-in-early-breast-cancer-929b3PDfjw
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605010-00001
Publisher site
See Article on Publisher Site

Abstract

Adjuvant tamoxifen has a significant survival benefit in early breast cancer but current data suggest that there is no further benefit beyond 5 years’ treatment. Extended adjuvant therapy with oral letrozole 2.5mg daily following 5 years of tamoxifen in postmenopausal women with hormone receptor-positive breast cancer was shown to significantly reduce the risk of recurrence compared with placebo in the MA-17 trial (predicted 4-year disease-free survival 95% vs 90%). A small but significant overall survival benefit has also emerged in the subset of patients with node-positive disease.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References